Mantis, N.J., Rol, N. & Corthesy, B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4, 603-611

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
Mucosal Immunology (Impact Factor: 7.37). 11/2011; 4(6):603-11. DOI: 10.1038/mi.2011.41
Source: PubMed


Secretory IgA (SIgA) serves as the first line of defense in protecting the intestinal epithelium from enteric toxins and pathogenic microorganisms. Through a process known as immune exclusion, SIgA promotes the clearance of antigens and pathogenic microorganisms from the intestinal lumen by blocking their access to epithelial receptors, entrapping them in mucus, and facilitating their removal by peristaltic and mucociliary activities. In addition, SIgA functions in mucosal immunity and intestinal homeostasis through mechanisms that have only recently been revealed. In just the past several years, SIgA has been identified as having the capacity to directly quench bacterial virulence factors, influence composition of the intestinal microbiota by Fab-dependent and Fab-independent mechanisms, promote retro-transport of antigens across the intestinal epithelium to dendritic cell subsets in gut-associated lymphoid tissue, and, finally, to downregulate proinflammatory responses normally associated with the uptake of highly pathogenic bacteria and potentially allergenic antigens. This review summarizes the intrinsic biological activities now associated with SIgA and their relationships with immunity and intestinal homeostasis.


Available from: Blaise Corthésy, Jul 02, 2014
  • Source
    • "It has been postulated that SIgA mediates immune exclusion at least in part by trapping microbes in the mucus layer overlying the epithelium of mucosal surfaces [20] [43]. An in vivo study in mice demonstrated that N-glycan side chains on the SC moiety anchor SIgA to the mucus gel lining the luminal surface of the respiratory tract [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Secretory IgA (SIgA) antibodies in the intestinal tract form the first line of antigen-specific immune defense, preventing access of pathogens as well as commensal microbes to the body proper. SIgA is transported into external secretions by the polymeric immunoglobulin receptor (pIgR). Evidence is reported here that the gut microbiota regulates production of SIgA and pIgR, which act together to regulate the composition and activity of the microbiota. SIgA in the intestinal mucus layer helps to maintain spatial segregation between the microbiota and the epithelial surface without compromising the metabolic activity of the microbes. Products shed by members of the microbial community promote production of SIgA and pIgR by activating pattern recognition receptors on host epithelial and immune cells. Maternal SIgA in breast milk provides protection to newborn mammals until the developing intestinal immune system begins to produce its own SIgA. Disruption of the SIgA-pIgR-microbial triad can increase the risk of infectious, allergic and inflammatory diseases of the intestine.
    Immunology Letters 12/2014; 162(2). DOI:10.1016/j.imlet.2014.05.008 · 2.51 Impact Factor
  • Source
    • "An inadequate or ineffective IgG response would allow virions to reach the epithelium where a SIgA response is elicited. Furthermore, it is known that SIgA is able to transport bound antigen across intestinal epithelium to dendritic cells in the gut-associated lymphoid tissue, increasing the possibility of infection [25]. This could explain why higher monomeric IgA antibodies in the serum correlated with risk of infection in the Thai RV144 vaccine trial. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Years of extensive research have yielded much knowledge in many aspects of HIV-1 infection, treatments, and education. However, without a vaccine, the number of people infected worldwide continues to grow. The partial success of the Thai RV144 vaccine trial provides hope that a method of protection is indeed possible. Understanding the mechanism behind the protection is critical if we hope to achieve our goal of inhibiting new infections of HIV-1. We hypothesize that the Fc of IgG binding protein (Fcgbp) is associated with the protection observed in the RV144 vaccine trial. It has the ability to trap viral-antibody complexes in the mucosa by binding the Fc of IgG to Fcgbp. This property could be used in the form of a microbicide containing antibodies to a variety of HIV-1 epitopes to prevent sexual transmission of HIV-1. The aim of this paper is to stimulate further research into Fcgbp and its role in innate immunity.
    The Open AIDS Journal 09/2014; 8(1):21-4. DOI:10.2174/1874613601408010021
  • Source
    • "The SIgA produced by activated B-cells is the main effector of the mucosal immune system and serve as a first line of defense to protect the gut epithelium from pathogenic microorganisms and noxious compounds (Corthesy, 2013). Also, SIgA promotes the clearance of antigens and pathogenic microorganisms from the intestinal lumen by entrapping them in mucus, blocking their access to epithelial receptors, and facilitating their removal by peristaltic and mucociliary activities (Mantis et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to investigate the effects of basal diets supplemented with a clay product consisting of zeolite and attapulgite (ZA) at 1:1 ratio on growth performance, digestibility of feed nutrients, activities of digestive enzymes in small intestine and intestinal health in broiler chickens. In experiment 1, 112 one-day-old male chickens were randomly divided into 2 groups with 8 replicates of 7 chickens each. In experiment 2, 84 one-day-old male chickens were randomly allocated into 2 groups consisting 6 replicates of 7 chickens each. The experimental diets both consisted of a maize-soybean basal control diet supplemented with 0% or 2% ZA. The diets were fed from 1 to 42 days of age. The results showed that ZA supplementation could increase body weight gain (BWG) and feed intake (FI), but had no significant effect on feed conversion ratio. The apparent digestibility values of crude protein and gross energy were significantly increased (p<0.05) by ZA from 14 to 16 d and 35 to 37 d. Dietary ZA treatment significantly increased (p<0.05) the activities of amylase, lipase and trypsin in jejunal digesta and the activities of maltase and sucrase in jejunal mucosa on days 21 and 42. The ZA supplementation also significantly increased (p<0.05) the catalase activity, reduced (p<0.05) the malondialdehyde concentration in the jejunal mucosa. In addition, a decrease of serum diamine oxidase activity and an increase (p<0.05) in concentration of secretory immunoglobulin A in jejunal mucosa were observed in birds treated with ZA on 21 and 42 days. It is concluded that ZA supplementation (2%) could partially improve the growth performance by increasing BWG and FI. This improvement was achieved through increasing the secretion of digestive enzymes, enhancing the digestibilites of nutrients, promoting intestinal health of broiler chickens.
    Asian Australasian Journal of Animal Sciences 09/2014; 27(9):1311-8. DOI:10.5713/ajas.2014.14241 · 0.54 Impact Factor
Show more